专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005094877A2 FORMULATION OF ANTIGEN 审中-公开
标题翻译：抗原配方
公开(公告)号：WO2005094877A2
公开(公告)日：2005-10-13
申请号：PCT/IB2005/002124
申请日：2005-03-17
申请人： DIAMYD MEDICAL AB
发明人： HARRIS, Robert , ROBERTSON, John , ESSEN-MOLLER, Anders
IPC分类号： A61K39/12
CPC分类号： A61K39/39 , A61K39/0008 , A61K2039/55505 , A61K2039/55516
摘要： The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the inventon may be used for diagnosis and amelioration of autoimmune diabetes in which the 65kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.
摘要翻译：本发明涉及用于诊断，预防和治疗疾病的方法和制剂。更具体地说，本发明教导了用于在自身免疫性疾病，变态反应，移植物排斥和癌症中用抗原进行诊断，预防和治疗的方法和制剂。实施例说明本发明的方法和制剂如何用于谷氨酸脱羧酶（GAD）的65kd同种型是主要抗原的自身免疫性糖尿病的诊断和改善。

2. 发明申请

WO2019162403A1 GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS 审中-公开
公开(公告)号：WO2019162403A1
公开(公告)日：2019-08-29
申请号：PCT/EP2019/054364
申请日：2019-02-21
申请人： DIAMYD MEDICAL AB
发明人： BIRNIR, Bryndis , HANNELIUS, Ulf , LINDQVIST, Anton
IPC分类号： A61K31/197 , A61P3/08
摘要： The present invention relates to methods for treatment or prevention of disorders caused influenced by dysfunction of β cells by administering to said patient a compound selected from the group consisting of GABA A receptor agonists. The invention further relates to in vitro methods for finding potentially useful pharmaceutical compounds.

3. 发明申请

WO2019059822A1 NEW FORMULATION OF GAMMA-AMINOBUTYRIC ACID 审中-公开
公开(公告)号：WO2019059822A1
公开(公告)日：2019-03-28
申请号：PCT/SE2018/050855
申请日：2018-08-24
申请人： DIAMYD MEDICAL AB
发明人： LINDQVIST, Anton , HANNELIUS, Ulf
IPC分类号： A61K31/197 , A61K9/22 , A61K47/38 , A61P3/10
摘要： The present invention relates to an oral dosage form comprising gamma-aminobutyric acid (GABA) and pharmaceutically acceptable excipients, wherein 100% of the GABA is released within 0.25-5hours in 0.01 M HC1 at 37°C in a USP dissolution apparatus 2. The invention further relates to specific dosage forms, methods for treatment of autoimmune diseases with the dosage form, as well as use of the dosage form in such methods.

4. 发明申请

WO2005102374A3 IMMUNOMODULATION BY A THERAPEUTIC MEDICATION INTENDED FOR TREATMENT OF DIABETES AND PREVENTION OF AUTOIMMUNE DIABETES 审中-公开
标题翻译：用于治疗糖尿病和预防自身免疫性糖尿病的治疗药物的免疫调节
公开(公告)号：WO2005102374A3
公开(公告)日：2006-03-16
申请号：PCT/IB2005002135
申请日：2005-03-03
申请人： DIAMYD MEDICAL AB
发明人： HARRIS ROBERT , ROBERTSON JOHN , ESSEN-MOLLER ANDERS
IPC分类号： A61K38/00 , A61K38/51 , A61K31/70 , A61K38/16 , A61K38/17 , A61K38/28
CPC分类号： A61K38/51
摘要： The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.
摘要翻译：本发明涉及用于治疗糖尿病和预防自身免疫性糖尿病的方法和制剂。本发明包括在药学上可接受的佐剂中施用人重组GAD65蛋白。

5. 发明申请

WO2019151939A1 NOVEL COMPOSITION AND USE THEREOF 审中-公开
公开(公告)号：WO2019151939A1
公开(公告)日：2019-08-08
申请号：PCT/SE2019/050097
申请日：2019-02-05
申请人： DIAMYD MEDICAL AB
发明人： HANNELIUS, Ulf , ESSEN-MÖLLER, Anders , LINDQVIST, Anton
IPC分类号： A61K39/00 , A61K9/127 , A61K31/197 , A61K31/59 , A61K33/06 , A61K33/242 , A61K38/17
摘要： The present invention relates to the use of at least two autoantigens specific to an autoimmune disease for treatment of said disease.The invention further relates to a method for treatment or prevention of an autoimmune disease, comprising administering to a subject such a pharmaceutical composition or administering to a subject at least two pharmaceutical compositions, each comprising at least one autoantigen which is not present in another such pharmaceutical composition, and which autoantigen is specific to an autoimmune disease.

6. 发明申请

WO2017058074A1 COMBINATION THERAPY USING GLIADIN AND GAMMA AMINOBUTYRIC ACID 审中-公开
标题翻译：使用谷氨酸和游离氨基酸的组合治疗
公开(公告)号：WO2017058074A1
公开(公告)日：2017-04-06
申请号：PCT/SE2016/050809
申请日：2016-08-30
申请人： DIAMYD MEDICAL AB
发明人： ESSEN-MÖLLER, Anders
IPC分类号： A61K38/16 , A61K31/197 , A61P7/00
CPC分类号： A61K31/197 , A61K38/168 , A61K39/0008 , A61K39/35 , A61K39/39 , C07K14/00 , C07K14/415
摘要： The present invention relates to the use of gliadin in medicine, in combination with gammma aminobutyric acid, and/or an antigen such as a beta cell autoantigen.
摘要翻译：本发明涉及药物中的麦醇溶蛋白与氨基丁酸和/或抗原如β细胞自身抗原的组合的用途。

7. 发明申请

WO2006013457A3 GAD2 GENE FOR POSSIBLE TREATMENT OF NERVOUS SYSTEM DISORDERS 审中-公开
标题翻译： GAD2基因可治疗神经系统疾病
公开(公告)号：WO2006013457A3
公开(公告)日：2006-04-06
申请号：PCT/IB2005002382
申请日：2005-03-17
申请人： DIAMYD MEDICAL AB , HARRIS ROBERT , ROBERTSON JOHN , ESSEN-MOLLER ANDERS
发明人： HARRIS ROBERT , ROBERTSON JOHN , ESSEN-MOLLER ANDERS
IPC分类号： A61K48/00 , A61K31/465 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： A61K48/00 , A61K31/465
摘要： The present invention regards methods and formulations for treatment of neurological and behavioural disorders eating disorders. More particularly, the present invention is applied to increase appetite in anorexic individuals or individuals with other eating disorders where an increase in appetite may be therapeutic. In the present invention, the GAD2 gene is inserted with a strong promoter, such as in an adenoassociated virus, and this is in turn administered into the paraventricular nucleus and other areas of the hypothalamus of anorexic individuals.
摘要翻译：本发明涉及用于治疗神经和行为障碍进食障碍的方法和制剂。更具体地说，本发明应用于增加食欲减退的个体或个体与其他进食障碍的食欲，其中食欲的增加可能是治疗性的。在本发明中，GAD2基因插入强启动子，例如在腺相关病毒中，然后又被施用于厌食个体的室旁核和下丘脑的其它区域。

8. 发明申请

WO2015187087A3 NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY 审中-公开
标题翻译：基于抗原治疗的新型组合
公开(公告)号：WO2015187087A3
公开(公告)日：2016-01-28
申请号：PCT/SE2015050651
申请日：2015-06-04
申请人： DIAMYD MEDICAL AB
发明人： ESSEN-MÖLLER ANDERS , LUDVIGSSON JOHNNY
IPC分类号： A61K39/00 , A61K31/592 , A61K31/593 , A61K38/28 , A61P3/10
CPC分类号： A61K39/0008 , A61K9/0019 , A61K31/192 , A61K31/197 , A61K31/592 , A61K31/593 , A61K38/1793 , A61K38/191 , A61K38/28 , A61K38/43 , A61K45/06 , A61K2039/54 , A61K2039/55505 , A61K2039/577 , C12Y401/01005 , A61K2300/00
摘要： The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, andto composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D, vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ Tcells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens.
摘要翻译：本发明涉及一种预防和/或治疗自身免疫性疾病的方法，包括向受试者施用包含至少一种β细胞自身抗原的所述组合物。所述受试者可具有高于50纳摩尔/ 或者组合物可以通过淋巴内注射或直接注射到淋巴结中，或在数周，数月或数年的时间内施用。本发明还涉及包含多个颗粒的组合物，每个颗粒在其表面上固定有至少一个第一和至少一个第二抗原，其中第一抗原是β细胞自身抗原，第二抗原是耐受原或 β细胞自身抗原，以及组合物，其包含i）至少一种β细胞自身抗原，和iia中的至少一种，IL-10诱导化合物，其选自维生素D，维生素-D类似物，酪氨酸激酶抑制剂，氨基丁酸和γ-氨基丁酸类似物; 和iib）降低树突状细胞激活初始CD4 + T细胞的能力的化合物，例如环氧合酶抑制剂，CTLA-4化合物或TNFα抑制剂。本发明还涉及药物试剂盒和β细胞自身抗原的医疗用途。

9. 发明申请

WO2015187087A2 NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY 审中-公开
标题翻译：基于抗原治疗的新型组合
公开(公告)号：WO2015187087A2
公开(公告)日：2015-12-10
申请号：PCT/SE2015/050651
申请日：2015-06-04
申请人： DIAMYD MEDICAL AB
发明人： ESSEN-MÖLLER, Anders , LUDVIGSSON, Johnny
IPC分类号： A61K39/00
CPC分类号： A61K39/0008 , A61K9/0019 , A61K31/192 , A61K31/197 , A61K31/592 , A61K31/593 , A61K38/1793 , A61K38/191 , A61K38/28 , A61K38/43 , A61K45/06 , A61K2039/54 , A61K2039/55505 , A61K2039/577 , C12Y401/01005 , A61K2300/00
摘要： The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, andto composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D, vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ Tcells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens.
摘要翻译：本发明涉及一种预防和/或治疗自身免疫性疾病的方法，包括向受试者施用包含至少一种β细胞自身抗原的所述组合物。所述受试者可具有高于50纳摩尔/ 或者组合物可以通过淋巴内注射或直接注射到淋巴结中，或在数周，数月或数年的时间内施用。本发明还涉及包含多个颗粒的组合物，每个颗粒在其表面上固定有至少一个第一和至少一个第二抗原，其中第一抗原是β细胞自身抗原，第二抗原是耐受原或 β细胞自身抗原，以及组合物，其包含i）至少一种β细胞自身抗原，和iia中的至少一种，IL-10诱导化合物，其选自维生素D，维生素-D类似物，酪氨酸激酶抑制剂，氨基丁酸和γ-氨基丁酸类似物; 和iib）降低树突状细胞激活初始CD4 + T细胞的能力的化合物，例如环氧合酶抑制剂，CTLA-4化合物或TNFα抑制剂。本发明还涉及药物试剂盒和β细胞自身抗原的医疗用途。

10. 发明申请

WO2005094877A3 FORMULATION OF GLUTAMIC ACID DECARBOXYLASE (GAD65) AND SERUM ALBUMIN 审中-公开
标题翻译：葡萄糖酸脱羧酶（GAD65）和血清白蛋白的配方
公开(公告)号：WO2005094877A3
公开(公告)日：2006-03-30
申请号：PCT/IB2005002124
申请日：2005-03-17
申请人： DIAMYD MEDICAL AB
发明人： HARRIS ROBERT , ROBERTSON JOHN , ESSEN-MOLLER ANDERS
IPC分类号： A61K39/00 , A61K39/12 , A61K39/39 , A61K39/000
CPC分类号： A61K39/39 , A61K39/0008 , A61K2039/55505 , A61K2039/55516
摘要： The present application deals with the use of glutamic acid decarboxylase (GAD) 65 for treating autoimmune diabetes.
摘要翻译：本申请涉及使用谷氨酸脱羧酶（GAD）65治疗自身免疫性糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式